Canada's
Leading Medical Cannabis Company Broadens Innovative Product
Portfolio to Growing Market in Australia
EDMONTON, AB, Feb. 20,
2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:
ACB) (TSX: ACB), the Canadian-based leading global medical cannabis
company, has announced today the company's extended pastille
offerings in Australia. This
expansion marks another meaningful step in Aurora's deep commitment
to offering patients a diverse range of high-quality, premium
medical cannabis products to meet their various needs and
interests.
"Expanding our portfolio of medical cannabis pastilles in
Australia demonstrates our
understanding of market demand and is another example of our
ability to bring high quality product to this key market as patient
interest increases," said Andre
Jerome, Executive Vice President of Global Business
Development at Aurora. "In this rapidly expanding market, we're
leveraging our unique capabilities, including global manufacturing
and excellence in navigating regulatory frameworks that define
Aurora's leadership."
Medical cannabis pastilles offer several key benefits, including
easy oral intake. The prolonged effects provide long-lasting and
extended relief after digestion. Pastilles also come in an
accessible format that is discrete, portable, and convenient.
The pastilles that are now available in Australia include:
- Aurora Pastilles - 10mg THC Pomegranate Berry (30 pack)
- Aurora Pastilles - 10:10 Balanced Pineapple (30 pack)
- Aurora Pastilles - 25mg CBD Acai Berry (30 pack)
Aurora maintains its position as the largest global medical
cannabis company operating in nationally legal markets. The company
has a robust innovation pipeline planned for global introduction
over the course of the coming months, bringing variety and new
options to patients.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the
medical and consumer markets across Canada, Europe, Australia and New
Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis
brands include MedReleaf, CanniMed, Aurora and Whistler Medical
Marijuana Co., as well as international brands, Pedanios, IndiMed
and CraftPlant. Aurora also has a controlling interest in Bevo
Farms Ltd., North America's
leading supplier of propagated agricultural plants. Driven by
science and innovation, and with a focus on high-quality cannabis
products, Aurora's brands continue to break through as industry
leaders in the medical, wellness and adult recreational markets
wherever they are launched. Learn more
at www.auroramj.com and follow us
on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
Forward Looking Information:
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include, but are not limited
to, statements regarding the Company's expanded pastilles offerings
in the Australian market, including the associated benefits to the
Company, as well as the benefits to the pastille format for
patients, and statements regarding expectations for the continued
rapid expansion of the Australian market, the Company's upcoming
innovation pipeline, and position as the largest medical global
cannabis company operating in nationally legal markets.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations (with respect to the Transaction and more generally with
respect to future acquisitions), management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises
and other risks, uncertainties and factors set out under the
heading "Risk Factors" in the Company's annual information from
dated June 20, 2024 (the "AIF") and
filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR+
at www.sedarplus.com and filed with and available on the
SEC's website at www.sec.gov. The Company cautions that the
list of risks, uncertainties and other factors described in the AIF
is not exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-expands-medical-cannabis-pastille-offerings-in-australia-302381814.html
SOURCE Aurora Cannabis Inc.
